Bat-Spit Drug May Improve Stroke Recovery
Drug Made From Vampire Bat Saliva Extends Stroke Treatment Window
WebMD News Archive
Feb. 9, 2004 (San Diego) -- Stroke experts say "time is brain," meaning that once stroke occurs each ticking of the clock makes permanent damage more likely. But an experimental drug developed from a mainstay of horror stories -- vampire bats -- appears capable of beating the deadly stroke clock.
The new drug is called desmoteplase and it takes its name from Desmodus rotundus, the scientific name for vampire bats. When a bat bites its victim, a component of the bat's saliva keeps the victim's blood flowing without clots forming. The new drug is a genetically engineered version of the bat-saliva clot buster.
Steven Warach, MD, PhD, chief of the section on stroke diagnostics and therapeutics at the National Institute of Neurological Disorders and Stroke (NINDS), tells WebMD early studies of desmoteplase suggest that the drug can reverse stroke symptoms including difficulty in speaking and paralysis in 60% of patients treated with the highest test dose of the drug. Warach and colleagues conducted dose and safety studies of the drug in 43 stroke patients. He presented the results at the 29th International Stroke Conference here.
Moreover, the drug is effective up to nine hours after stroke onset, which is three times as long as the three-hour treatment window of the currently available clot-busting drug, tPA.
This type of stroke, which is called an ischemic stroke, accounts for 88% of the 700,000 new strokes diagnosed in the United States each year.
Warach says desmoteplase differs in a number of ways from tPA, including the possibility that it can dissolve a clot without increasing the risk of bleeding in other areas of the body -- especially in other regions of the brain, which is a well-recognized risk with tPA.
Warach's study did more than just test doses of a new -- and potentially breakout -- drug, it also tested a new method for identifying patients who could benefit from clot-busting treatment. He says that in the 10 years since the FDA approve tPA, stroke experts have been frustrated by the fact that tPA does not work in all patients. Estimates are that only about one in eight patients actually benefit. "So patient selection is extremely important," he says.